Castle Biosciences, Inc. Common Stock
CSTL
CSTL: Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
moreShow CSTL Financials
Recent trades of CSTL by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CSTL's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Diagnostic test for predicting metastasis and recurrence in cutaneous melanoma Sep. 06, 2022
-
Patent Title: Diagnostic test for predicting metastasis and recurrence in cutaneous melanoma Mar. 03, 2020
Federal grants, loans, and purchases
- $14,450 2023-06-30 00:00:00 Agency: Department of Veterans Affairs
- $12,500 2023-06-20 00:00:00 Agency: Department of Veterans Affairs
- $125,000 2022-09-07 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $14,450 2022-05-17 00:00:00 Agency: None
- $0 2021-08-10 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $36,550 2021-07-01 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $37,400 2020-05-06 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Followers on CSTL's company Twitter account
Number of mentions of CSTL in WallStreetBets Daily Discussion
Recent insights relating to CSTL
Recent picks made for CSTL stock on CNBC
ETFs with the largest estimated holdings in CSTL
Flights by private jets registered to CSTL